0.00%
11.15%
6.46%
-0.21%
15.42%
-20.09%
-12.06%
AI Spotlight on ROG
Company Description
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally.The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation.It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases.
In addition, the company supplies diagnostic instruments and reagents.The company was founded in 1896 and is headquartered in Basel, Switzerland.
Market Data
| Last Price | 285.2 |
| Change Percentage | 0.00% |
| Open | 289 |
| Previous Close | 285.2 |
| Market Cap ( Millions) | 230039 |
| Volume | 720065 |
| Year High | 289.6 |
| Year Low | 212.9 |
| M A 50 | 259.63 |
| M A 200 | 258.95 |
Financial Ratios
| FCF Yield | 4.96% |
| Dividend Yield | 3.37% |
| ROE | 36.46% |
| Debt / Equity | 124.99% |
| Net Debt / EBIDTA | 178.13% |
| Price To Book | 7.87 |
| Price Earnings Ratio | 21.46 |
| Price To FCF | 20.14 |
| Price To sales | 3.85 |
| EV / EBITDA | 14.85 |
News
- 09:24 - Roche Holding AG (RHHVF) Expands AI in Digital Pathology and Drug Development, Reports 9% Sales Growth in Q3 2024
- 07:28 - Roche Holding AG (RHHBF) (FY 2024) Earnings Call Highlights: Strong Sales Growth and Strategic ...
- Jan -30 - Roche's 2024 Sales and Earnings Beat, Key Drugs Perform Well
- Jan -30 - FDA grants 510(k) clearance to Roche’s Tina-quant molarity assay
- Jan -30 - Roche Expects Sales, Earnings Growth After Better-Than-Expected Results
- Jan -30 - Roche sees high single-digit core profit growth in 2025
- Jan -30 - [Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2024 results with 7% sales growth; fourth quarter marks third straight quarter of 9% growth
- Jan -29 - Roche appoints chief digital technology officer
- Jan -29 - Change to the Roche Enlarged Corporate Executive Committee
- Jan -28 - Roche reports positive topline outcomes from DMD treatment trial
- Jan -28 - Roche’s Itovebi demonstrated statistically significant and clinically meaningful overall survival benefit in a certain type of HR-positive advanced breast cancer
- Jan -28 - Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
- Jan -27 - Roche announces new results from EMBARK demonstrating significant sustained benefits of Elevidys in ambulatory individuals with Duchenne muscular dystrophy (DMD)
- Jan -23 - Roche’s STI assay panels gain FDA 510(k) clearance and CLIA waiver
- Jan -22 - Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care
- Jan -16 - Roche’s new deals head tries to navigate a more ‘complicated’ and ‘expensive’ biotech world
- Jan -13 - Roche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma
- Jan -10 - Alzheimer’s Drugs Eyed by Investors Seeking Obesity-Like Gains
- Jan -09 - Roche's momentum in digital pathology continues with FDA clearance on its high-volume slide scanner
- Jan -08 - Roche to complete $1.5 billion acquisition of U.S. biopharma company Poseida
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Pharmaceuticals
Expected Growth : 2.5 %
What the company do ?
Roche Holding AG's Pharmaceuticals segment develops and commercializes prescription medicines for various therapeutic areas, including oncology, immunology, and ophthalmology.
Why we expect these perspectives ?
Roche Holding AG's pharmaceutical segment growth of 2.5% is driven by increasing demand for oncology and immunology treatments, strong sales of recently launched products such as Tecentriq and Ocrevus, and expansion into emerging markets. Additionally, strategic acquisitions and partnerships, as well as investments in digital healthcare and personalized medicine, contribute to the segment's growth.
Segment n°2 -> Diagnostics
Expected Growth : 3.5 %
What the company do ?
Diagnostics from Roche Holding AG refers to the company's diagnostic division that develops and manufactures diagnostic instruments, tests, and software for healthcare professionals.
Why we expect these perspectives ?
Roche's Diagnostics segment growth is driven by increasing demand for personalized healthcare, adoption of digital diagnostics, and expansion in emerging markets. The company's innovative product portfolio, including molecular diagnostics and point-of-care testing, also contributes to growth. Additionally, strategic acquisitions and partnerships enhance Roche's market position and drive revenue growth.
Roche Holding Ag Products
| Product Range | What is it ? |
|---|---|
| Diagnostics | Roche Diagnostics is a global leader in in vitro diagnostics, offering a broad portfolio of diagnostic solutions for healthcare professionals. |
| Pharmaceuticals | Roche Pharmaceuticals develops and commercializes innovative medicines for oncology, immunology, ophthalmology, and neuroscience. |
| Sequencing Solutions | Roche Sequencing Solutions provides next-generation sequencing (NGS) and polymerase chain reaction (PCR) technologies for research and diagnostics. |
| Molecular Diagnostics | Roche Molecular Diagnostics offers a range of molecular diagnostic tests for infectious diseases, cancer, and genetic disorders. |
| Tissue Diagnostics | Roche Tissue Diagnostics provides instruments and reagents for tissue-based cancer diagnostics and research. |
| Point of Care | Roche Point of Care offers handheld and benchtop analyzers for near-patient testing in hospitals, clinics, and physician offices. |
Roche Holding AG's Porter Forces
Threat Of Substitutes
Roche Holding AG has a moderate threat of substitutes due to the presence of alternative pharmaceutical companies and generic drug manufacturers. However, the company's strong brand reputation and patented products mitigate this threat to some extent.
Bargaining Power Of Customers
Roche Holding AG has a low bargaining power of customers due to its strong brand reputation and patented products, which gives the company significant pricing power. Additionally, the company's products are often reimbursed by healthcare systems, reducing the bargaining power of individual customers.
Bargaining Power Of Suppliers
Roche Holding AG has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and services. However, the company's large scale of operations and long-term contracts with suppliers mitigate this threat to some extent.
Threat Of New Entrants
Roche Holding AG has a low threat of new entrants due to the high barriers to entry in the pharmaceutical industry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise.
Intensity Of Rivalry
Roche Holding AG operates in a highly competitive pharmaceutical industry, with several large multinational corporations competing for market share. The company's strong brand reputation, patented products, and significant research and development investments help to mitigate this threat to some extent.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 50.16% |
| Debt Cost | 3.95% |
| Equity Weight | 49.84% |
| Equity Cost | 4.72% |
| WACC | 4.33% |
| Leverage | 100.63% |
Roche Holding AG : Quality Control
Roche Holding AG passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| AZN.L | AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, … |
| SAN.PA | Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, … |
| GSK.L | GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the … |
| BAYN.DE | Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for … |
| NOVN.SW | Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Novartis
A-Score
1-Year Total Return ->
🥈
Sanofi
A-Score
1-Year Total Return ->
🥉
Roche
A-Score
1-Year Total Return ->
4
GSK
A-Score
1-Year Total Return ->
5
AstraZeneca
A-Score
1-Year Total Return ->
6
